Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverPEN
HealthcareNYQUSD

Penumbra, Inc.

$001234567890012345678900123456789.0012345678900123456789-0.1%
52w low $221.26$362.41 52w high
Market data · updated 16h ago
Market data
Market cap
$12.46B
52w range
$221.26 - $362.41
Beta
0.70
Sector
Healthcare
Data quality
96/100
Valuation
P/E ratio
73.0x
fair value estimate
$126.69
Margin of safety
-60.1%
Forward P/E
50.9x
PEG ratio
4.07
Quality & efficiency
Moat score
70/100
Return on equity
12.7%
Profit margin
11.8%
Debt / equity
0.15
Growth & analysts
Revenue growth
+15.6%
Analyst target
$363.36
Target upside
+14.4%
Analysts
14
Run the 10-point checklist before you buy How these numbers are made

About Penumbra, Inc.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Valuation

ValueGrowthProfitHealthIncome38QUALITY
Overall Rating
41
Low quality
Low quality

Derived from filed metrics · High confidence (96% of the inputs available)

Moat Score70
Fair value estimate
$126.69-60.1% downside

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$12.46B
P/E Ratio
73.0
Dividend Yield
0.00%
Revenue Growth
+15.6%
Profit Margin
11.8%
ROE
12.7%
Debt / Equity
0.15
Beta
0.70

Statistics

Similar Stocks · Healthcare

Latest News · PEN